{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:35Z","timestamp":1793726015272,"version":"4.6.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":253,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pliant Therapeutics, Inc"},{"name":"Pliant Therapeutics, Inc"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Idiopathic pulmonary fibrosis (IPF) is characterized by excessive deposition of type I collagen. 68Ga-CBP8, a type I collagen positron emission tomography probe, measures collagen accumulation and shows higher collagen deposition in patients with IPF. Bexotegrast (PLN-74809) is an oral, once-daily, dual-selective inhibitor of \u03b1v\u03b26 and \u03b1v\u03b21 integrins under late-stage evaluation for treatment of IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate changes in type I collagen in the lungs of participants with IPF after treatment with bexotegrast.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase 2 (NCT05621252), single-center, double-blind, placebo-controlled study, adults with IPF received bexotegrast 160 mg or placebo for 12 weeks. The primary endpoint was the change in whole-lung standardized uptake value of 68Ga-CBP8 positron emission tomography. Changes in lung dynamic contrast-enhanced magnetic resonance imaging parameters, FVC, cough severity, and biomarkers of collagen synthesis and progressive disease were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Of 10 participants, 7 received bexotegrast and 3 received placebo. At Week 12, the mean change from baseline in the top quartile of 68Ga-CBP8 whole-lung standardized uptake value was \u22121.2% with bexotegrast versus 6.6% with placebo; the greatest mean changes were observed in subpleural lung regions in both groups (bexotegrast, \u22123.7%; placebo, 10.3%). Dynamic contrast-enhanced magnetic resonance imaging showed numerically increased peak enhancement and faster contrast washout rate in bexotegrast-treated participants, suggesting improvements in lung microvasculature and decreased extravascular extracellular volume. Bexotegrast treatment resulted in numerical improvements in FVC, cough severity, and biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The reduced uptake of 68Ga-CBP8 in the lungs of participants with IPF indicates an antifibrotic effect of bexotegrast, suggesting the potential for favorable lung remodeling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202410-1934oc","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T14:44:55Z","timestamp":1743173095000},"page":"1229-1240","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":29,"title":["Dual \u03b1v\u03b26 and \u03b1v\u03b21 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial"],"prefix":"10.1093","volume":"211","author":[{"given":"Sydney B.","family":"Montesi","sequence":"first","affiliation":[{"name":"Divison of Pulmonary and Critical Care Medicine and"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Turner","sequence":"additional","affiliation":[{"name":"Former employee of Pliant Therapeutics, Inc., South San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Y.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-5033","authenticated-orcid":false,"given":"Nikos","family":"Efthimiou","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Susnjar","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-5971","authenticated-orcid":false,"given":"Ciprian","family":"Catana","sequence":"additional","affiliation":[{"name":"Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Fromson","sequence":"additional","affiliation":[{"name":"Divison of Pulmonary and Critical Care Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Clark","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Decaris","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris N.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric A.","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Caravan","sequence":"additional","affiliation":[{"name":"Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2026031105353014400_bib1","first-page":"797","article-title":"Idiopathic pulmonary fibrosis","volume":"379","author":"Lederer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026031105353014400_bib2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105353014400_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1165\/rcmb.2014-0150OC","article-title":"Pathologic regulation of collagen I by an aberrant protein phosphatase 2A\/histone deacetylase C4\/microRNA-29 signal axis in idiopathic pulmonary fibrosis fibroblasts","volume":"53","author":"Khalil","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026031105353014400_bib4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3389\/fphys.2017.00777","article-title":"The processes and mechanisms of cardiac and pulmonary fibrosis","volume":"8","author":"Murtha","year":"2017","journal-title":"Front Physiol"},{"key":"2026031105353014400_bib5","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1164\/ajrccm\/140.6.1693","article-title":"An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis","volume":"140","author":"Kuhn","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"2026031105353014400_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1165\/rcmb.2012-0335OC","article-title":"Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts","volume":"48","author":"Marinkovic","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026031105353014400_bib7","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1172\/JCI66700","article-title":"Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis","volume":"123","author":"Zhou","year":"2013","journal-title":"J Clin Invest"},{"key":"2026031105353014400_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1164\/rccm.201508-1546OC","article-title":"Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis","volume":"194","author":"Ley","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105353014400_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12890-019-0996-2","article-title":"Comparison of disease progression subgroups in idiopathic pulmonary fibrosis","volume":"19","author":"K\u00e4rkk\u00e4inen","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026031105353014400_bib10","doi-asserted-by":"crossref","first-page":"713698","DOI":"10.3389\/fmed.2021.713698","article-title":"Gender differences in idiopathic pulmonary fibrosis: are men and women equal?","volume":"8","author":"Ses\u00e9","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026031105353014400_bib11","doi-asserted-by":"crossref","first-page":"17534666231181537","DOI":"10.1177\/17534666231181537","article-title":"Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective","volume":"17","author":"Mai","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"2026031105353014400_bib12","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jpainsymman.2019.12.364","article-title":"Idiopathic pulmonary fibrosis: a review of disease, pharmacological, and nonpharmacological strategies with a focus on symptoms, function, and health-related quality of life","volume":"59","author":"Rozenberg","year":"2020","journal-title":"J Pain Symptom Manage"},{"key":"2026031105353014400_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12026-022-09267-y","article-title":"Research progress on drugs targeting the TGF-beta signaling pathway in fibrotic diseases","volume":"70","author":"Shi","year":"2022","journal-title":"Immunol Res"},{"key":"2026031105353014400_bib14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1165\/rcmb.2015-0391TR","article-title":"Transforming growth factor-beta: master regulator of the respiratory system in health and disease","volume":"54","author":"Aschner","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026031105353014400_bib15","doi-asserted-by":"crossref","first-page":"e20190103","DOI":"10.1084\/jem.20190103","article-title":"Transforming growth factor-beta in tissue fibrosis","volume":"217","author":"Frangogiannis","year":"2020","journal-title":"J Exp Med"},{"key":"2026031105353014400_bib16","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3390\/ijms19082460","article-title":"TGF-beta signaling in lung health and disease","volume":"19","author":"Saito","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026031105353014400_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1183\/09031936.00210414","article-title":"\u03b1v\u03b26 integrin may be a potential prognostic biomarker in interstitial lung disease","volume":"46","author":"Saini","year":"2015","journal-title":"Eur Respir J"},{"key":"2026031105353014400_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.200706-805OC","article-title":"Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation","volume":"177","author":"Horan","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105353014400_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12931-021-01863-0","article-title":"Dual inhibition of \u03b1v\u03b26 and \u03b1v\u03b21 reduces fibrogenesis in lung tissue explants from patients with IPF","volume":"22","author":"Decaris","year":"2021","journal-title":"Respir Res"},{"key":"2026031105353014400_bib20","doi-asserted-by":"crossref","first-page":"12215","DOI":"10.1073\/pnas.92.26.12215","article-title":"Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated","volume":"92","author":"Diebold","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026031105353014400_bib21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","article-title":"Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF study","volume":"210","author":"Lancaster","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105353014400_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1164\/rccm.201903-0503LE","article-title":"Type I collagen-targeted positron emission tomography imaging in idiopathic pulmonary fibrosis: first-in-human studies","volume":"200","author":"Montesi","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105353014400_bib23","doi-asserted-by":"crossref","first-page":"eaaf4696","DOI":"10.1126\/scitranslmed.aaf4696","article-title":"Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models","volume":"9","author":"Desogere","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026031105353014400_bib24","doi-asserted-by":"crossref","first-page":"e034363","DOI":"10.1161\/JAHA.124.034363","article-title":"Simultaneous positron emission tomography and molecular magnetic resonance imaging of cardiopulmonary fibrosis in a mouse model of left ventricular dysfunction","volume":"13","author":"Moon","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026031105353014400_bib25","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1164\/rccm.202210-1884LE","article-title":"Dynamic contrast-enhanced MRI demonstrates pulmonary microvascular abnormalities months after SARS-CoV-2 infection","volume":"207","author":"Zhou","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105353014400_bib26","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1148\/radiol.2015141876","article-title":"T1-weighted dynamic contrast-enhanced MR imaging of the lung in asthma: semiquantitative analysis for the assessment of contrast agent kinetic characteristics","volume":"278","author":"Zhang","year":"2016","journal-title":"Radiology"},{"key":"2026031105353014400_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/1522-2586(200008)12:2<224::AID-JMRI3>3.0.CO;2-E","article-title":"Perfusion magnetic resonance imaging of the lung: characterization of pneumonia and chronic obstructive pulmonary disease. A feasibility study","volume":"12","author":"Amundsen","year":"2000","journal-title":"J Magn Reson Imaging"},{"key":"2026031105353014400_bib28","doi-asserted-by":"crossref","first-page":"00907-02020","DOI":"10.1183\/23120541.00907-2020","article-title":"Dynamic contrast-enhanced magnetic resonance imaging of the lung reveals important pathobiology in idiopathic pulmonary fibrosis","volume":"7","author":"Montesi","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026031105353014400_bib29","first-page":"OA1058","article-title":"Bexotegrast reduces type 1 collagen deposition in participants with idiopathic pulmonary fibrosis (IPF) after 12 weeks of therapy [abstract]","volume":"64","author":"Montesi","year":"2024","journal-title":"Eur Respir J"},{"key":"2026031105353014400_bib30","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105353014400_bib31","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1164\/rccm.202010-3994ED","article-title":"2020 American Thoracic Society BEAR Cage Winning Proposal: collagen-targeted positron emission tomography imaging as a novel biomarker of treatment response in idiopathic pulmonary fibrosis","volume":"203","author":"Montesi","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105353014400_bib32","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.2967\/jnumed.110.079962","article-title":"68Ga-DOTANOC PET\/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results","volume":"51","author":"Ambrosini","year":"2010","journal-title":"J Nucl Med"},{"key":"2026031105353014400_bib33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00259-013-2514-8","article-title":"Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients","volume":"41","author":"Win","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026031105353014400_bib34","doi-asserted-by":"crossref","first-page":"17534666211004238","DOI":"10.1177\/17534666211004238","article-title":"The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis","volume":"15","author":"Kim","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"2026031105353014400_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1874306402014010022","article-title":"Effects of nintedanib on quantitative lung fibrosis score in idiopathic pulmonary fibrosis","volume":"14","author":"Lancaster","year":"2020","journal-title":"Open Respir Med J"},{"key":"2026031105353014400_bib36","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.diii.2013.10.010","article-title":"Perfusion and vascular permeability: basic concepts and measurement in DCE-CT and DCE-MRI","volume":"94","author":"Cuenod","year":"2013","journal-title":"Diagn Interv Imaging"},{"key":"2026031105353014400_bib37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/thoraxjnl-2019-214375","article-title":"Quantification of pulmonary perfusion in idiopathic pulmonary fibrosis with first pass dynamic contrast-enhanced perfusion MRI","volume":"76","author":"Weatherley","year":"2021","journal-title":"Thorax"},{"key":"2026031105353014400_bib38","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ajpath.2014.02.003","article-title":"Matrix biology of idiopathic pulmonary fibrosis: a workshop report of the National Heart, Lung, and Blood Institute","volume":"184","author":"Thannickal","year":"2014","journal-title":"Am J Pathol"},{"key":"2026031105353014400_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jcmg.2017.04.006","article-title":"Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy","volume":"11","author":"Nakamori","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026031105353014400_bib40","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1148\/radiol.2018180051","article-title":"Quantification of liver fibrosis at T1 and T2 mapping with extracellular volume fraction MRI: preclinical results","volume":"288","author":"Luetkens","year":"2018","journal-title":"Radiology"},{"key":"2026031105353014400_bib41","doi-asserted-by":"crossref","first-page":"e137519","DOI":"10.1172\/jci.insight.137519","article-title":"Age-dependent regulation of cell-mediated collagen turnover","volume":"5","author":"Podolsky","year":"2020","journal-title":"JCI Insight"},{"key":"2026031105353014400_bib42","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1440-1843.2011.01996.x","article-title":"Cough predicts prognosis in idiopathic pulmonary fibrosis","volume":"16","author":"Ryerson","year":"2011","journal-title":"Respirology"},{"key":"2026031105353014400_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11739-018-1960-5","article-title":"The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis","volume":"14","author":"Bargagli","year":"2019","journal-title":"Intern Emerg Med"},{"key":"2026031105353014400_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1465-9921-10-40","article-title":"Expression of transforming growth factor-beta (TGF-beta) in chronic idiopathic cough","volume":"10","author":"Xie","year":"2009","journal-title":"Respir Res"},{"key":"2026031105353014400_bib45","doi-asserted-by":"crossref","first-page":"17534666211049743","DOI":"10.1177\/17534666211049743","article-title":"Validation of a visual analog scale for assessing cough severity in patients with chronic cough","volume":"15","author":"Martin Nguyen","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"2026031105353014400_bib46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12931-019-1118-7","article-title":"Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort","volume":"20","author":"Organ","year":"2019","journal-title":"Respir Res"},{"key":"2026031105353014400_bib47","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","article-title":"Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis","volume":"10","author":"Bowman","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026031105353014400_bib48","doi-asserted-by":"crossref","first-page":"e0158047","DOI":"10.1371\/journal.pone.0158047","article-title":"Amplification of TGFbeta induced ITGB6 gene transcription may promote pulmonary fibrosis","volume":"11","author":"Tatler","year":"2016","journal-title":"PLoS One"},{"key":"2026031105353014400_bib49","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1007\/s12325-023-02668-x","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis in subgroups with differing baseline characteristics","volume":"40","author":"Kolb","year":"2023","journal-title":"Adv Ther"},{"key":"2026031105353014400_bib50","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","article-title":"Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS","volume":"193","author":"Costabel","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105353014400_bib51","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"key":"2026031105353014400_bib52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1164\/rccm.202007-2638LE","article-title":"Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease","volume":"203","author":"Gallay","year":"2021","journal-title":"Am J Respir Crit Care Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/7\/1229\/67295898\/ajrccm_211_7_1229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/7\/1229\/67295898\/ajrccm_211_7_1229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:35:45Z","timestamp":1773221745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/211\/7\/1229\/8513676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202410-1934oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2024-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}